Trial tests Immune-Boosting drug to wipe out prostate cancer
NCT ID NCT06528210
Summary
This study aimed to see if adding the immunotherapy drug pembrolizumab to standard hormone therapy and radiation could better eliminate cancer in men with high-risk prostate cancer that hasn't spread. The main goal was to check if a follow-up biopsy showed no cancer after treatment. The trial was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE I PROSTATE CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.